Related Experiment Video
Updated: May 7, 2025
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Targeting AURKA with multifunctional nanoparticles in CRPC therapy
Bin Deng1,2, Binghu Ke1, Qixing Tian1
1Department of Urology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, China.
Abstract:
Castration-resistant prostate cancer (CRPC) presents significant therapeutic challenges due to its aggressive nature and poor prognosis. Targeting Aurora-A kinase (AURKA) has shown promise in cancer treatment. This study investigates the efficacy of ART-T cell membrane-encapsulated AMS@AD (CM-AMS@AD) nanoparticles (NPs) in a photothermal-chemotherapy-immunotherapy combination for CRPC. Bioinformatics analysis of the Cancer Genome Atlas-prostate adenocarcinoma (TCGA-PRAD) dataset revealed overexpression of AURKA in PCa, correlating with poor clinical outcomes. Single-cell RNA sequencing data from the GEO database showed a significant reduction in immune cells in CRPC. Experimentally, T cell membrane-biomimetic NPs loaded with the AURKA inhibitor Alisertib and chemotherapy drug DTX were synthesized and characterized by dynamic light scattering and transmission electron microscopy, showing good stability and uniformity (average diameter: 158 nm). In vitro studies demonstrated that these NPs inhibited CRPC cell proliferation, increased the G2/M cell population, and elevated apoptosis, confirmed by γH2AX expression. In vivo, CM-AMS@AD NPs accumulated in tumor tissues, significantly slowed tumor growth, decreased proliferation, increased apoptosis, and improved the immune environment, enhancing dendritic cell (DC) maturation and increasing CD8 + /CD4 + ratios. These findings suggest that CM-AMS@AD NPs offer a promising triple-combination therapy for CRPC, integrating photothermal, chemotherapy, and immunotherapy, with significant potential for future clinical applications.
Insights
This study introduces novel nanoparticles combining photothermal therapy, chemotherapy, and immunotherapy to treat castration-resistant prostate cancer (CRPC). The treatment effectively inhibits tumor growth and enhances the anti-tumor immune response in preclinical models.
Area of Science:
- Oncology
- Nanotechnology
- Immunotherapy
Background:
- Castration-resistant prostate cancer (CRPC) is a challenging malignancy with limited treatment options.
- Aurora-A kinase (AURKA) is overexpressed in prostate cancer (PCa) and linked to poor outcomes.
- CRPC is often associated with a suppressed immune microenvironment.
Purpose of the Study:
- To investigate the efficacy of T cell membrane-encapsulated nanoparticles (CM-AMS@AD) as a triple-combination therapy (photothermal, chemotherapy, immunotherapy) for CRPC.
- To evaluate the anti-tumor effects and immune modulation of CM-AMS@AD NPs in vitro and in vivo.
Main Methods:
- Bioinformatics analysis of TCGA-PRAD and GEO datasets to identify AURKA overexpression and immune cell reduction in CRPC.
- Synthesis and characterization of T cell membrane-biomimetic nanoparticles loaded with Alisertib (AURKA inhibitor) and DTX (chemotherapy drug).
- In vitro assays assessing cell proliferation, cell cycle, and apoptosis; in vivo studies evaluating tumor growth, apoptosis, and immune cell profiles.
Main Results:
- CM-AMS@AD NPs demonstrated good stability and uniformity (158 nm average diameter).
- In vitro, NPs inhibited CRPC cell proliferation, arrested cells in G2/M phase, and induced apoptosis.
- In vivo, NPs accumulated in tumors, significantly suppressed tumor growth, promoted apoptosis, enhanced dendritic cell maturation, and improved CD8+/CD4+ T cell ratios.
Conclusions:
- CM-AMS@AD NPs represent a promising strategy for CRPC treatment by integrating photothermal, chemotherapy, and immunotherapy.
- This novel nanoparticle formulation shows significant potential for clinical translation in managing advanced prostate cancer.
More Related Videos
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
